

# David M Mutch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5708025/publications.pdf>

Version: 2024-02-01

167  
papers

6,902  
citations

94433

37  
h-index

71685

76  
g-index

172  
all docs

172  
docs citations

172  
times ranked

8846  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. <i>Journal of Clinical Oncology</i> , 2009, 27, 1419-1425.  | 1.6  | 645       |
| 2  | Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2811-2818.  | 1.6  | 371       |
| 3  | Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2317-2326.  | 27.0 | 326       |
| 4  | Proteogenomic Characterization of Endometrial Carcinoma. <i>Cell</i> , 2020, 180, 729-748.e26.  | 28.9 | 296       |
| 5  | Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions. <i>Gynecologic Oncology</i> , 2007, 107, 159-162.   | 1.4  | 257       |
| 6  | 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. <i>Gynecologic Oncology</i> , 2014, 133, 401-404.  | 1.4  | 251       |
| 7  | Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5908-5913.  | 7.1  | 216       |
| 8  | Microsatellite Instability and Epigenetic Inactivation of MLH1 and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type. <i>Journal of Clinical Oncology</i> , 2007, 25, 2042-2048.   | 1.6  | 186       |
| 9  | Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. <i>Gynecologic Oncology</i> , 2013, 129, 277-284.  | 1.4  | 185       |
| 10 | Combined Microsatellite Instability, <i>MLH1</i> Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4301-4308. | 1.6  | 163       |
| 11 | Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. <i>Nature Medicine</i> , 2017, 23, 1046-1054.   | 30.7 | 145       |
| 12 | Polymerase É (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing. <i>Cancer</i> , 2015, 121, 386-394.   | 4.1  | 142       |
| 13 | Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3062-3068.   | 1.6  | 141       |
| 14 | Unraveling the Genetics of Human Obesity. <i>PLoS Genetics</i> , 2006, 2, e188.   | 3.5  | 130       |
| 15 | Clinical significance of microsatellite instability in endometrial carcinoma. <i>Cancer</i> , 2000, 89, 1758-1764.  | 4.1  | 117       |
| 16 | A review of the associations between single nucleotide polymorphisms in taste receptors, eating behaviors, and health. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 194-207.   | 10.3 | 115       |
| 17 | Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals. <i>FASEB Journal</i> , 2015, 29, 748-758.  | 0.5  | 101       |
| 18 | Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. <i>Genes Chromosomes and Cancer</i> , 1997, 18, 219-227.  | 2.8  | 98        |

| #  | ARTICLE  | IF    | CITATIONS |
|----|--|-------|-----------|
| 19 | Recurrent gestational trophoblastic disease. Experience of the southeastern regional trophoblastic disease center. <i>Cancer</i> , 1990, 66, 978-982.  | 4.1   | 88        |
| 20 | An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 148, 174-180.  | 1.4   | 83        |
| 21 | Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 141, 312-317.  | 1.4   | 75        |
| 22 | Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. <i>Cancer</i> , 2017, 123, 3261-3268.   | 4.1   | 72        |
| 23 | New therapies for advanced, recurrent, and metastatic endometrial cancers. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 19.  | 3.6   | 72        |
| 24 | <i>ATR</i> Mutation in Endometrioid Endometrial Cancer Is Associated With Poor Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2009, 27, 3091-3096.   | 1.6   | 71        |
| 25 | Polyunsaturated fatty acid regulation of adipocyte FADS1 and FADS2 expression and function. <i>Obesity</i> , 2015, 23, 725-728.  | 3.0   | 71        |
| 26 | A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 441-445.  | 1.4   | 69        |
| 27 | The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 287-298.   | 329.8 | 65        |
| 28 | An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. <i>Gynecologic Oncology</i> , 2017, 147, 243-249. | 1.4   | 61        |
| 29 | Evaluation of Ovarian Cancer: Initial Application of Coregistered Photoacoustic Tomography and US. <i>Radiology</i> , 2018, 289, 740-747.  | 7.3   | 60        |
| 30 | Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1088-1097.   | 0.8   | 57        |
| 31 | FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. <i>Gynecologic Oncology</i> , 2020, 157, 639-643.  | 1.4   | 57        |
| 32 | Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. <i>Gynecologic Oncology</i> , 2017, 145, 519-525.   | 1.4   | 52        |
| 33 | Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. <i>Gynecologic Oncology</i> , 2015, 137, 7-13.  | 1.4   | 47        |
| 34 | Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. <i>British Journal of Cancer</i> , 2018, 118, 72-78.  | 6.4   | 46        |
| 35 | Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. , 1999, 85, 119-126.   |       | 44        |
| 36 | Individual Saturated and Monounsaturated Fatty Acids Trigger Distinct Transcriptional Networks in Differentiated 3T3-L1 Preadipocytes. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2013, 6, 1-15.  | 1.3   | 43        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. <i>Gynecologic Oncology</i> , 2021, 161, 113-121.  | 1.4  | 42        |
| 38 | Surgical management of ovarian cancer. <i>Seminars in Oncology</i> , 2002, 29, 3-8.   | 2.2  | 40        |
| 39 | Hereditary Ovarian Cancer and Risk Reduction. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 31-48.   | 2.8  | 40        |
| 40 | Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 968-977.   | 1.6  | 38        |
| 41 | Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. <i>Gynecologic Oncology</i> , 2016, 141, 134-139.  | 1.4  | 37        |
| 42 | Update on Prognostic Markers for Endometrial Cancer. <i>Women's Health</i> , 2014, 10, 277-288.   | 1.5  | 34        |
| 43 | Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 649-657.   | 0.8  | 34        |
| 44 | Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database. <i>Gynecologic Oncology</i> , 2017, 146, 572-579.  | 1.4  | 34        |
| 45 | Gemcitabine in cervical cancer. <i>Gynecologic Oncology</i> , 2003, 90, S8-S15.   | 1.4  | 33        |
| 46 | Variation in the FADS1/2 gene cluster alters plasma n <sup>6</sup> PUFA and is weakly associated with hsCRP levels in healthy young adults. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013, 89, 257-263.   | 2.2  | 33        |
| 47 | Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes. <i>Advances in Radiation Oncology</i> , 2017, 2, 148-158.   | 1.2  | 33        |
| 48 | Lifestyle genomics and the metabolic syndrome: A review of genetic variants that influence response to diet and exercise interventions. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 2028-2039.  | 10.3 | 33        |
| 49 | RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 935-939.   | 1.3  | 32        |
| 50 | Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, .   | 6.3  | 32        |
| 51 | Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 389-398.   | 4.1  | 32        |
| 52 | The Role of FADS1/2 Polymorphisms on Cardiometabolic Markers and Fatty Acid Profiles in Young Adults Consuming Fish Oil Supplements. <i>Nutrients</i> , 2014, 6, 2290-2304.   | 4.1  | 30        |
| 53 | A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naïve patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5500-5500. | 1.6  | 29        |
| 54 | Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw251.   | 6.3  | 28        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 379-389.  | 0.8 | 28        |
| 56 | Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. <i>Neoplasia</i> , 2017, 19, 100-111.  | 5.3 | 27        |
| 57 | Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2881-2891.   | 4.1 | 27        |
| 58 | The <i>FOXA2</i> transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. <i>Cancer</i> , 2018, 124, 65-73.  | 4.1 | 27        |
| 59 | The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice. <i>Obstetrics and Gynecology</i> , 2007, 110, 155-167.   | 2.4 | 26        |
| 60 | AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. <i>Oncotarget</i> , 2016, 7, 77291-77305.   | 1.8 | 26        |
| 61 | Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors. <i>Oncologist</i> , 2017, 22, 377-e37.  | 3.7 | 25        |
| 62 | Pathology of cancers of the female genital tract including molecular pathology. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 93-108.  | 2.3 | 24        |
| 63 | Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. <i>Cancer</i> , 1994, 74, 1891-1898.   | 4.1 | 23        |
| 64 | Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial. <i>Gynecologic Oncology</i> , 2015, 139, 70-76.   | 1.4 | 23        |
| 65 | Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 766.e1-766.e9.   | 1.3 | 23        |
| 66 | A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2019, 152, 548-553. | 1.4 | 23        |
| 67 | Overexpression of enhancer of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2020, 156, 423-429.  | 1.4 | 23        |
| 68 | Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. <i>Oncotarget</i> , 2017, 8, 84579-84594.             | 1.8 | 23        |
| 69 | Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 309-314.   | 1.4 | 22        |
| 70 | Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study. <i>Metabolomics</i> , 2018, 14, 154.  | 3.0 | 22        |
| 71 | Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 147, 648-653.  | 1.4 | 21        |
| 72 | Single Nucleotide Polymorphisms in Taste Receptor Genes Are Associated with Snacking Patterns of Preschool-Aged Children in the Guelph Family Health Study: A Pilot Study. <i>Nutrients</i> , 2018, 10, 153.  | 4.1 | 21        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Frequent deletion of chromosome 1p sequences in an aggressive histologic subtype of endometrial cancer. <i>Human Molecular Genetics</i> , 1996, 5, 1017-1021.   | 2.9 | 20        |
| 74 | Low frequency of CDKN2 mutation in endometrial carcinomas. <i>Molecular Carcinogenesis</i> , 1995, 13, 210-212.   | 2.7 | 19        |
| 75 | Gemcitabine combination chemotherapy of ovarian cancer. <i>Gynecologic Oncology</i> , 2003, 90, S16-S20.  | 1.4 | 19        |
| 76 | Adjuvant radiotherapy in Stage II endometrial carcinoma: Is brachytherapy alone sufficient for local control?. <i>Brachytherapy</i> , 2015, 14, 427-432.  | 0.5 | 19        |
| 77 | Sex Differences in Blood HDL, the Total Cholesterol/HDL Ratio, and Palmitoleic Acid are Not Associated with Variants in Common Candidate Genes. <i>Lipids</i> , 2017, 52, 969-980.  | 1.7 | 19        |
| 78 | p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts. <i>Scientific Reports</i> , 2019, 9, 4762.   | 3.3 | 19        |
| 79 | CAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress. <i>Molecular Cancer Research</i> , 2022, 20, 265-279.                                       | 3.4 | 19        |
| 80 | TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3289-3300. | 1.6 | 19        |
| 81 | Genotypic and phenotypic progression in endometrial tumorigenesis: Determining when defects in DNA mismatch repair and KRAS2 occur. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 295-301.  | 2.8 | 18        |
| 82 | Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: A population-based analysis. <i>Gynecologic Oncology</i> , 2014, 133, 242-249.   | 1.4 | 18        |
| 83 | Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 151, 18-23.                | 1.4 | 18        |
| 84 | Guiding Global Best Practice in Personalized Nutrition Based on Genetics: The Development of a Nutrigenomics Care Map. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2022, 122, 259-269.   | 0.8 | 18        |
| 85 | Lymphnode staging update in the American Joint Committee on Cancer 8th Edition cancer staging manual. <i>Gynecologic Oncology</i> , 2018, 150, 7-8.   | 1.4 | 17        |
| 86 | Optical Resolution Photoacoustic Microscopy of Ovary and Fallopian Tube. <i>Scientific Reports</i> , 2019, 9, 14306.  | 3.3 | 17        |
| 87 | Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 134, 24-28.  | 1.4 | 16        |
| 88 | The clinical management of inoperable endometrial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 515-521.  | 2.4 | 16        |
| 89 | Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer. <i>Cancer Research</i> , 2019, 79, 196-208.  | 0.9 | 16        |
| 90 | Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. <i>Oncotarget</i> , 2017, 8, 68758-68768.   | 1.8 | 15        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic (NC) cell activity. <i>Cancer</i> , 1990, 65, 466-472.  | 4.1 | 14        |
| 92  | Hereditary gynecologic cancers. <i>International Journal of Gynecology and Obstetrics</i> , 2014, 124, 189-192.  | 2.3 | 14        |
| 93  | Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. <i>Gynecologic Oncology</i> , 2018, 148, 49-55.                      | 1.4 | 14        |
| 94  | SOX11 hypermethylation as a tumor biomarker in endometrial cancer. <i>Biochimie</i> , 2019, 162, 8-14.   | 2.6 | 14        |
| 95  | A novel algorithm for network-based prediction of cancer recurrence. <i>Genomics</i> , 2019, 111, 17-23.   | 2.9 | 14        |
| 96  | Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer. <i>PLoS ONE</i> , 2017, 12, e0190125.  | 2.5 | 14        |
| 97  | What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. <i>Cancer</i> , 2017, 123, 985-993.           | 4.1 | 13        |
| 98  | Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. <i>Radiotherapy and Oncology</i> , 2017, 122, 445-451. | 0.6 | 12        |
| 99  | Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 459.e1-459.e11.                | 1.3 | 12        |
| 100 | Gynecologic Oncologists'™ Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic Oncology. <i>Gynecologic and Obstetric Investigation</i> , 2019, 84, 50-55.                       | 1.6 | 12        |
| 101 | Dietary EPA and DHA prevent changes in white adipose tissue omega-3 PUFA and oxylipin content associated with a <i>Fads2</i> deficiency. <i>Journal of Nutritional Biochemistry</i> , 2019, 63, 140-149.                   | 4.2 | 12        |
| 102 | Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic <i>via</i> hierarchical binding events at the plasma membrane. <i>Oncotarget</i> , 2016, 7, 31534-31549.                           | 1.8 | 12        |
| 103 | Synuclein $\beta$ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. <i>Cancer</i> , 2017, 123, 1144-1155.  | 4.1 | 11        |
| 104 | Histogram analysis of en face scattering coefficient map predicts malignancy in human ovarian tissue. <i>Journal of Biophotonics</i> , 2019, 12, e201900115.   | 2.3 | 11        |
| 105 | Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use. <i>Gynecologic Oncology</i> , 2019, 153, 356-361.       | 1.4 | 11        |
| 106 | Modified frailty index is predictive of wound complications in obese patients undergoing gynecologic surgery via a midline vertical incision. <i>Gynecologic Oncology</i> , 2020, 157, 287-292.                            | 1.4 | 11        |
| 107 | Molecular staging of gynecological cancer: What is the future?. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2015, 29, 776-789.  | 2.8 | 10        |
| 108 | Which patients with inoperable vulvar cancer may benefit from brachytherapy in addition to external beam radiation? A Surveillance, Epidemiology, and End Results analysis. <i>Brachytherapy</i> , 2017, 16, 831-840.      | 0.5 | 10        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2017, 147, 460-464.   | 1.4 | 10        |
| 110 | Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6â€ year follow-up study. <i>Gynecologic Oncology</i> , 2019, 155, 88-92.   | 1.4 | 10        |
| 111 | Treatment Compliance as a Major Barrier to Optimal Cervical Cancer Treatment in Guatemala. <i>Journal of Global Oncology</i> , 2019, 5, 1-5.   | 0.5 | 10        |
| 112 | Clinical outcomes after isolated pelvic failure in cervical cancer patients treated with definitive radiation. <i>Gynecologic Oncology</i> , 2019, 153, 530-534.   | 1.4 | 10        |
| 113 | Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination. <i>Cancer Research</i> , 2019, 79, 2662-2668.  | 0.9 | 10        |
| 114 | Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1157-1161.              | 2.5 | 10        |
| 115 | Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259). <i>Journal of Clinical Oncology</i> , 2022, 40, 1464-1473.                                      | 1.6 | 10        |
| 116 | Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 138, 614-619.  | 1.4 | 9         |
| 117 | MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization. <i>Journal of the National Cancer Institute</i> , 2018, 110, 517-526.  | 6.3 | 9         |
| 118 | FADS1 genotype is distinguished by human subcutaneous adipose tissue fatty acids, but not inflammatory gene expression. <i>International Journal of Obesity</i> , 2019, 43, 1539-1548.   | 3.4 | 9         |
| 119 | Squamous cell carcinoma of the vulva: a review of present management and future considerations. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 43-50.  | 2.4 | 9         |
| 120 | The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women. <i>Gynecologic Oncology</i> , 2021, 160, 660-668.          | 1.4 | 9         |
| 121 | Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial. <i>Gynecologic Oncology</i> , 2021, 162, 770-777.  | 1.4 | 9         |
| 122 | Two sisters with Mayer-Rokitansky-K ster-Hauser syndrome and serous adenocarcinoma of the ovary. <i>Gynecologic Oncology Reports</i> , 2017, 22, 13-15.  | 0.6 | 8         |
| 123 | Variants in <b><i>APOA5</i></b> and <b><i>ADIPOQ</i></b> Moderate Improvements in Metabolic Syndrome during a One-Year Lifestyle Intervention. <i>Lifestyle Genomics</i> , 2018, 11, 80-89.  | 1.7 | 8         |
| 124 | Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with <sup>18</sup>F-fluorodeoxyglucoseâ€ positron emission tomography in stage IB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1351-1354. | 2.5 | 8         |
| 125 | Incorporation of Porcine Adenovirus 4 Fiber Protein Enhances Infectivity of Adenovirus Vector on Dendritic Cells: Implications for Immune-Mediated Cancer Therapy. <i>PLoS ONE</i> , 2015, 10, e0125851.   | 2.5 | 7         |
| 126 | Impact of the COVID-19 pandemic on referral to and delivery of gynecologic oncology care. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100928.  | 0.6 | 7         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. <i>Human Mutation</i> , 2016, 37, 1004-1012.  | 2.5 | 6         |
| 128 | Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology. <i>Scientific Reports</i> , 2016, 6, 22661.  | 3.3 | 6         |
| 129 | Patients with endometrial cancer continue to lack understanding of their risks for cancer. <i>Gynecologic Oncology Reports</i> , 2019, 29, 106-110.   | 0.6 | 6         |
| 130 | Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 136-140.                                  | 0.6 | 6         |
| 131 | GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2019, 153, 335-342. | 1.4 | 6         |
| 132 | Impact of employment and insurance status on distress in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2021, 161, 477-482.   | 1.4 | 6         |
| 133 | Factors influencing residents' interest in gynecologic oncology fellowship. <i>Gynecologic Oncology Reports</i> , 2019, 30, 100504.   | 0.6 | 5         |
| 134 | Tumor Lysis Syndrome in a Patient With Metastatic Endometrial Cancer Treated With Lattice Stereotactic Body Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100797.   | 1.2 | 5         |
| 135 | Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. <i>Gynecologic Oncology</i> , 2022, 164, 428-436.                   | 1.4 | 5         |
| 136 | GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1348-1359.  | 4.1 | 5         |
| 137 | No evidence for BCL10 mutation in endometrial cancers with microsatellite instability. <i>Human Mutation</i> , 2001, 17, 117-121.   | 2.5 | 4         |
| 138 | Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 1-5.  | 0.6 | 4         |
| 139 | A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy. <i>Gynecologic Oncology</i> , 2021, 161, 700-704.  | 1.4 | 4         |
| 140 | Can Molecular Diagnostics Usher in a New Era for Screening, Diagnosis, and Treatment of Ovarian Cancer?. <i>Obstetrics and Gynecology</i> , 2014, 124, 870-872.   | 2.4 | 3         |
| 141 | Awareness of the association between obesity and peri-operative risk among newly diagnosed patients with complex atypical hyperplasia and endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2015, 12, 41-44.  | 0.6 | 3         |
| 142 | The future role of molecular staging in gynecologic cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S127-31.   | 2.3 | 3         |
| 143 | The promise of molecular staging for the future. <i>Cancer</i> , 2017, 123, 728-730.  | 4.1 | 3         |
| 144 | SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth. <i>Gynecologic Oncology</i> , 2018, 151, 337-344.   | 1.4 | 3         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 145 | A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education. <i>Gynecologic Oncology</i> , 2020, 159, 209-213.                         | 1.4  | 3         |
| 146 | Association between rs174537 <i>FADS1</i> polymorphism and immune cell profiles in abdominal and femoral subcutaneous adipose tissue: an exploratory study in adults with obesity. <i>Adipocyte</i> , 2021, 10, 124-130. | 2.8  | 3         |
| 147 | The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2021, 35, 100694.                 | 0.6  | 3         |
| 148 | Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer. <i>Cancers</i> , 2021, 13, 5877.  | 3.7  | 3         |
| 149 | The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 263.  | 2.6  | 3         |
| 150 | Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?. <i>Gynecologic Oncology Reports</i> , 2019, 29, 20-24.  | 0.6  | 2         |
| 151 | The Dawning of the Age of Personalized Medicine in Gynecologic Oncology. <i>Cancers</i> , 2020, 12, 3135.  | 3.7  | 2         |
| 152 | Polymorphisms in the stearoyl-CoA desaturase gene modify blood glucose response to dietary oils varying in MUFA content in adults with obesity. <i>British Journal of Nutrition</i> , 2022, 127, 503-512.                | 2.3  | 2         |
| 153 | Discussion: "Accuracy of preoperative endometrial sampling"™ by Huang et al. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 196, e1-e6.  | 1.3  | 1         |
| 154 | A Case Report Demonstrating Unambiguous Clinical Utility of Pet/CT Scanning in Recurrent Ovarian Cancer. <i>Case Reports in Oncology</i> , 2009, 2, 121-124.   | 0.7  | 1         |
| 155 | Targeted therapy in endometrial cancer: Making progress. <i>Cancer</i> , 2016, 122, 3428-3429.   | 4.1  | 1         |
| 156 | Unethical randomised controlled trial of cervical screening in India: US Freedom of Information Act disclosures. <i>BMJ Global Health</i> , 2017, 2, e000177.  | 4.7  | 1         |
| 157 | Postpartum salpingectomy: a procedure whose time has come. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 8-9.  | 1.3  | 1         |
| 158 | Prediction modelling of 1-year outcomes to a personalized lifestyle intervention for Canadians with metabolic syndrome. <i>Applied Physiology, Nutrition and Metabolism</i> , 2020, 45, 621-627.                         | 1.9  | 1         |
| 159 | The emerging role of precision medicine in the treatment of endometrial cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 87-93.  | 0.7  | 1         |
| 160 | The IARC Perspective on Cervical Cancer Screening. <i>New England Journal of Medicine</i> , 2022, 386, 607-608.  | 27.0 | 1         |
| 161 | Diagnosis and Management of Precancerous Cervical Lesions. <i>Current Obstetrics and Gynecology Reports</i> , 2014, 3, 128-135.  | 0.8  | 0         |
| 162 | Effect of Tumor Stage on Surveillance Strategies After Treatment for Ovarian Cancer. <i>Journal of Gynecologic Surgery</i> , 2015, 31, 326-330.  | 0.1  | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Premature Judgment of Uterine Morcellation: Look at the Data Before You Leap. Journal of the National Cancer Institute, 2015, 107, djv283.                                     | 6.3 | 0         |
| 164 | Reply. American Journal of Obstetrics and Gynecology, 2017, 216, 192-193.  | 1.3 | 0         |
| 165 | Genes and Cancer. , 2018, , 493-527.e6.  |     | 0         |
| 166 | Abstract PO045: Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer. , 2021, , .   |     | 0         |
| 167 | The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies. Gynecologic Oncology, 2022, , . | 1.4 | 0         |